IBRX vs URGN: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
IBRX is the larger of the two ($6.54B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 0.17). URGN is the smaller challenger ($1.55B), expected to make money next year (12.67x forward earnings): more room to run, but more to prove. If you believe the upside is worth bigger swings, URGN fits (beta 1.64). If you want the steadier ride, IBRX fits (beta 0.17).
IBRX vs URGN: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | IBRX | URGN | What it tells you |
|---|---|---|---|
| Market cap | $6.54B | $1.55B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -20.50 | 12.67 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.17 | 1.64 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 40% of range | 44% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Before you buy: how IBRX and URGN affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IBRX and URGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IBRX and URGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does ImmunityBio (IBRX) do?
ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy. Its approved use is in combination with BCG for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The original April 2024 approval covered carcinoma in situ (CIS); on October 14, 2026 the FDA expanded the label to include patients whose tumors are papillary-only, which the company says is the first FDA approval for that group. Papillary disease accounts for roughly 85% of the NMIBC population by the company's figures, so the change widens the eligible pool considerably. The company is also pushing label expansions into BCG-naive bladder cancer and lung cancer while building out global commercial partnerships across roughly 33 to 34 countries. The founder and largest shareholder, Patrick Soon-Shiong, remains central to the story and its strategy.
What does UroGen Pharma (URGN) do?
UroGen Pharma (Nasdaq: URGN) develops and sells drugs that treat urothelial cancers without surgery. Its core technology is RTGel, a reverse-thermal hydrogel that is liquid when cold and turns to gel at body temperature, which lets a chemotherapy agent sit against tumor tissue in the bladder or upper urinary tract long enough to work. Two products built on it are approved. Jelmyto, cleared in 2020, treats low-grade upper tract urothelial cancer. Zusduri, cleared in June 2025, treats recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and is the first FDA-approved alternative to repeated transurethral resection surgery for that population. Behind them sit UGN-103 (a reformulated follow-on whose NDA the FDA accepted in October 2026, with a June 14, 2027 PDUFA target date), UGN-104 in upper tract disease, and UGN-501, an oncolytic virus that dosed its first Phase 1 patient in November 2026. The company has about 300 employees and is run by CEO Liz Barrett.
IBRX vs URGN: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- IBRX drivers: Anktiva revenue ramp; Label and indication expansion.
- URGN drivers: The Zusduri launch curve; Operating leverage arriving faster than expected.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: IBRX carries the full risk profile of an unprofitable commercial-stage biotech. For URGN, the company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025.
IBRX or URGN: which should you pick?
If the story you believe is IBRX's (Anktiva revenue ramp), IBRX is the more direct way to own it; if it is URGN's (The Zusduri launch curve), URGN is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IBRX and URGN guides.
IBRX vs URGN: the full fundamentals
IBRX. The valuation is still demanding: a roughly $6.5 billion market value against about $183 million of trailing revenue is a price-to-sales multiple near 36, down from about 60 in October after the post-earnings drop, and it prices in the 2027 consensus of roughly $352 million of revenue and beyond. The company is not profitable, analysts expect a loss of about $0.93 per share in 2026 and about $0.30 in 2027, and it funds ongoing losses partly through financing, so cash runway and dilution are central to the story. The four analysts Yahoo Finance tracks carry a mean target near $14.25.
URGN. There is no meaningful trailing P/E because UroGen is still loss-making over the last twelve months, roughly ~$66M of net loss, so the shares are framed on sales multiples and on how quickly the Zusduri ramp closes the gap. About ~$1.55B of market value against ~$250M of trailing revenue is roughly 6x sales, and analysts' 2027 estimates (revenue near $535M, EPS near $2.50) put the forward P/E around 13x, which is what the stock is being priced on; the mean analyst target of ~$60.71 from seven analysts sits well above the price. Debt and the RTW obligation still matter here, unlike for a cash-rich clinical-stage biotech, and the next data point is fourth-quarter results in early 2027.
Headline figures (approximate, November 2026): IBRX shows revenue (ttm) ~$183M, revenue growth (q3 2026 yoy) ~53%; down ~4% vs Q2, q3 2026 revenue ~$48.8M vs ~$57M to $61M expected, net loss (ttm) ~$1.11B (EPS ~-$1.06); URGN shows market cap ~$1.55B (~$31.68 per share, November 20, 2026), revenue (ttm) ~$250M (latest quarter up ~224% year over year), revenue (q3 2026) ~$89.0M (Zusduri ~$68.0M, Jelmyto ~$21.0M), net loss (q3 2026 / ttm) ~$1.5M (~$0.03 per share, vs ~$0.11 profit expected) / ~$66M.
The bottom line: IBRX vs URGN
IBRX and URGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined IBRX and URGN exposure against your real portfolio. It is not an investment adviser.
Wondering how IBRX or URGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about ImmunityBio
Ask Walnut's AI anything about IBRX and see how it fits what you own.
FAQ
What is the difference between IBRX and URGN?
+
ImmunityBio (IBRX) is a clinical- and commercial-stage immunotherapy company built around Anktiva (nogapendekin alfa inbakicept), an IL-15 receptor agonist immunotherapy. UroGen Pharma (Nasdaq: URGN) develops and sells drugs that treat urothelial cancers without surgery. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is IBRX or URGN the better stock?
+
Neither is universally better. IBRX is the larger incumbent; URGN is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, IBRX or URGN?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both IBRX and URGN?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of IBRX vs URGN?
+
IBRX: IBRX carries the full risk profile of an unprofitable commercial-stage biotech. It reported large net losses in 2026 (about $633 million in the first quarter, $230 million in the second and $185 million in the third, inflated by non-cash items), and trailing twelve-month operating cash outflow was about $288 million, or roughly $72 million a quarter, which repeatedly requires financing that can dilute existing shareholders. Cash stood near $334 million at September 30, 2026 against about $1.3 billion of debt. Losses per share missed consensus in the second and third quarters, and third-quarter research and selling costs rose about 40% and 49%, a reminder that the path to breakeven is not smooth. Anktiva sales also slipped sequentially for the first time in the third quarter. Its market value (about $6.5 billion) is roughly 36 times trailing revenue of about $183 million, and the stock is still up about threefold in 2026 even after a 25% one-month drop, so any slowdown in adoption, a negative regulatory decision, competitive pressure, or a difficult capital raise could move the stock sharply. Single-drug concentration and dependence on continued Anktiva execution compound these risks. URGN: The company still runs a shareholders' deficit of ~$125M, with ~$90.5M of cash and marketable securities against ~$196M of term debt and a prepaid forward obligation to RTW, and liquidity fell from ~$120.5M at the end of 2025. Its own filings frame going-concern as dependent on Jelmyto and Zusduri cash inflows plus the ability to raise capital, though management states it has funding beyond one year, and at-the-market equity capacity makes dilution an available lever. Concentration risk is severe: two products, one delivery technology, and one therapeutic area, with Zusduri now about three quarters of revenue after roughly a year on the market. A launch curve this steep can flatten quickly if reimbursement, site onboarding, or repeat prescribing stalls, and sequential growth already slowed from ~73% to ~35% in the third quarter. Competition is arriving from several directions at once, including newly approved intravesical therapies in adjacent bladder cancer settings, competing clinical trials that management says are pulling Jelmyto patient starts, and cheap compounded chemotherapy regimens that urology practices already use. Jelmyto faces generic entry in September 2030 and Zusduri loses regulatory exclusivity in June 2028, so the patent running to 2044 has to hold up to be worth what the market is assigning it. The share price itself has become a risk signal: the stock fell about 32% over the three months to November 20, 2026, from a 52-week high of about $50.81, and dropped after the third-quarter EPS miss, while options implied volatility has been rising.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell IBRX or URGN; figures are approximate and dated (as of November 2026). Verify current data before investing.